Mazdutide: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข3 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Store prefilled pens at 2-8C (refrigerator). Protect from light. Do not freeze. In-use pens may be stored at room temperature (below 30C) for up to 21 days. Discard after 21 days at room temperature or after expiration date.
Protocol Quick-Reference
Weight management and glycemic control via dual GLP-1/glucagon receptor agonism
Dosing
Amount
4 mg, 6 mg, or 9 mg weekly (maintenance)
Frequency
Once weekly
Duration
Chronic therapy (ongoing)
Step-wise Titration
Administration
Route
SCSchedule
Once weekly
Timing
Any time of day, with or without meals; same day each week
โ Rotate injection sites
Cycle
Duration
Chronic therapy (ongoing)
Repeatable
Yes
Preparation & Storage
โ Ready-to-use โ no reconstitution required
Storage: Store prefilled pens at 2-8C (refrigerator). Protect from light. Do not freeze. In-use pens may be stored at room temperature (below 30C) for up to 21 days. Discard after 21 days at room temperature or after expiration date.
โ๏ธ Suggested Bloodwork (6 tests)
HbA1c and fasting glucose
When: Baseline
Why: Baseline glycemic status
CMP with liver enzymes
When: Baseline
Why: Baseline metabolic and hepatic function
Lipid panel
When: Baseline
Why: Baseline cardiovascular risk markers
Lipase and amylase
When: Baseline
Why: Baseline pancreatic enzymes
TSH
When: Baseline
Why: Thyroid function baseline
HbA1c
When: 3 months
Why: Assess glycemic improvement
๐ก Key Considerations
- โMissed dose: take within 3 days of scheduled dose; if more than 3 days, skip and resume on regular schedule
- โContraindication: Contraindicated in personal/family history of medullary thyroid carcinoma or MEN2; not studied in severe hepatic/renal impairment
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Obesity/weight management (approved indication, China) | 4 mg, 6 mg, or 9 mg SC | Once weekly | Ongoing (chronic treatment) | Gradual dose escalation from starting dose. Phase III GLORY trials demonstrated 10-20% weight loss at 48-60 weeks depending on dose. 9 mg dose achieved up to 20.1% weight loss. |
| Type 2 diabetes (clinical trial) | 3 mg, 4.5 mg, or 6 mg SC | Once weekly | 24 weeks (Phase II trial duration) | Phase II trial showed HbA1c reduction of -1.57% (4 mg) and -2.15% (6 mg) vs -0.14% placebo at week 24. Dose-dependent glycemic improvement. |
| Phase 1b obesity dose-finding | 9 mg and 10 mg SC | Once weekly | 12 weeks | Multiple-ascending-dose study. Mean weight loss of -11.7% (9 mg) vs -1.8% (placebo) at 12 weeks. Established tolerability of higher doses. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Mazdutide is provided as a ready-to-use prefilled injection pen or solution. No reconstitution is required for the commercial formulation. For research formulations, reconstitute lyophilized powder with sterile water per manufacturer instructions.
Recommended Injection Sites
- โAbdomen (subcutaneous, preferred site)
- โThigh (subcutaneous)
- โUpper arm (subcutaneous)
๐งStorage Requirements
Store prefilled pens at 2-8C (refrigerator). Protect from light. Do not freeze. In-use pens may be stored at room temperature (below 30C) for up to 21 days. Discard after 21 days at room temperature or after expiration date.
Community Dosing Protocols
Compare these clinical doses with what 5+ community members report using.
Based on 5+ community reports
View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Dosing Information#
Approved Dosing (China)#
Weight Management#
Mazdutide was approved in China in June 2025 for weight management in adults with obesity (BMI >= 28 kg/m2) or overweight (BMI >= 24 kg/m2) with at least one weight-related comorbidity. The dosing involves gradual escalation to minimize gastrointestinal side effects.
Dose Escalation Schedule#
The typical dose escalation approach used in clinical trials follows a stepwise increase every 4 weeks:
| Week | Dose | Purpose |
|---|---|---|
| 1-4 | Starting dose (e.g., 1.5-3 mg) | Initiation and GI adaptation |
| 5-8 | Intermediate dose | Continued titration |
| 9-12 | Target maintenance dose | Approaching therapeutic dose |
| 13+ | Maintenance (4 mg, 6 mg, or 9 mg) | Long-term treatment |
The gradual escalation allows the gastrointestinal system to adapt to GLP-1 receptor activation, significantly reducing the incidence and severity of nausea, vomiting, and diarrhea compared to starting at the full maintenance dose.
Clinical Trial Dosing Data#
Phase III Obesity Trials (GLORY Program)#
The GLORY-2 Phase III trial evaluated three maintenance doses in Chinese adults with obesity or overweight:
4 mg Maintenance Dose:
- Body weight reduction: -10.09% at week 48
- 73.9% of participants achieved at least 5% weight loss
- Lower GI adverse event rates vs higher doses
6 mg Maintenance Dose:
- Body weight reduction: -12.55% at week 48
- 82.0% of participants achieved at least 5% weight loss
- Moderate GI adverse event profile
9 mg Maintenance Dose:
- Body weight reduction: up to -20.1% at week 60
- Highest efficacy but also highest GI adverse event rates
- Achieved -18.55% mean weight loss vs -3.02% placebo at week 60
Phase II Type 2 Diabetes Trial#
In the Phase II trial for type 2 diabetes, the following dosing results were observed at 24 weeks:
| Dose | HbA1c Change | Body Weight Change |
|---|---|---|
| 3 mg weekly | -1.35% | -5.4% |
| 4.5 mg weekly | -1.57% | -7.2% |
| 6 mg weekly | -2.15% | -9.3% |
| Placebo | -0.14% | -0.3% |
Phase 1b High-Dose Study#
A multiple-ascending-dose Phase 1b study evaluated 9 mg and 10 mg doses in Chinese adults with overweight or obesity over 12 weeks. The 9 mg cohort achieved -11.7% mean body weight reduction at 12 weeks vs -1.8% with placebo, establishing the tolerability and efficacy of higher doses that were subsequently tested in Phase III.
Administration#
Injection Technique#
Mazdutide is administered by subcutaneous injection once weekly, on the same day each week. The injection may be given at any time of day, with or without food. Injection should be administered in the abdomen, thigh, or upper arm, with rotation of injection sites each week.
Prefilled Pen Instructions#
The commercial formulation in China is provided as a prefilled injection pen for patient self-administration:
- Remove the pen from refrigerator 30 minutes before use to reach room temperature
- Inspect the solution: it should be clear and colorless to slightly yellowish
- Attach a new pen needle
- Prime the pen per manufacturer instructions
- Select the prescribed dose
- Choose the injection site and clean with an alcohol swab
- Insert the needle at a 90-degree angle and inject
- Hold the needle in place for 10 seconds after injection
- Safely dispose of the needle after each use
Missed Doses#
If a dose is missed, it should be administered as soon as possible within 3 days of the scheduled dose. If more than 3 days have elapsed, skip the missed dose and administer the next dose on the regularly scheduled day. Do not administer two doses within 3 days of each other.
Dose Adjustment Considerations#
Hepatic Impairment#
No dose adjustment is recommended for mild to moderate hepatic impairment based on available data. Mazdutide has not been studied in severe hepatic impairment; use with caution.
Renal Impairment#
No dose adjustment is recommended for mild to moderate renal impairment. Data in severe renal impairment or end-stage renal disease is limited; use with caution and monitor closely.
Elderly Patients#
No specific dose adjustment is recommended based on age alone. Elderly patients may be more susceptible to GI adverse events and dehydration; careful dose titration is advisable.
Switching from Other GLP-1 Agonists#
No formal switching studies have been published. When transitioning from another GLP-1 receptor agonist, the prior agent should typically be discontinued and mazdutide started according to the standard dose escalation schedule.
Storage Guidelines#
Prefilled Pens#
- Before first use: Store at 2-8 degrees Celsius (refrigerator). Do not freeze.
- In-use: May be stored at room temperature (below 30 degrees Celsius) for up to 21 days
- Protection: Keep away from direct light and heat
- Discard: After 21 days at room temperature, or after the expiration date on the label
Research Formulations#
Lyophilized research-grade mazdutide should be stored at -20 degrees Celsius. Reconstituted solutions should be refrigerated at 2-8 degrees Celsius and used within the timeframe specified by the manufacturer.
Evidence Gaps#
- Optimal dose for specific patient subgroups (varying BMI ranges, ethnic backgrounds) not fully characterized
- Long-term dose maintenance vs dose reduction strategies not studied
- Combination dosing with other anti-obesity agents not evaluated
- Dose adjustment for significant drug interactions not established
- Pharmacokinetics in severe organ impairment incompletely characterized
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Mazdutide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.